Carlos Perez
Internal Medicine · Bayamon, PRNPI 1669447256
Payments from drug & device makers
Across 154 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$944
- Boehringer Ingelheim$501
- Johnson & Johnson$457
- GSK$451
- Eli Lilly Export S.A. Puerto Rico Branch$350
- Lilly USA, LLC$339
- plus $1K from 11 others
What the payments were for
- Speaking & faculty fees$2005%
- Food & beverage$3,86395%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $944 |
| Boehringer Ingelheim | 15 | $501 |
| Johnson & Johnson | 20 | $457 |
| GSK | 20 | $451 |
| Eli Lilly Export S.A. Puerto Rico Branch | 16 | $350 |
| Lilly USA, LLC | 6 | $339 |
| Sanofi-aventis U.S. LLC | 1 | $200 |
| E.r. Squibb & Sons, L.L.C. | 9 | $194 |
| PBG Puerto Rico LLC | 8 | $180 |
| Novo Nordisk | 4 | $150 |
| Pfizer | 3 | $74 |
| Amgen | 3 | $71 |
| AbbVie | 3 | $70 |
| Genmab U.S., Inc. | 2 | $39 |
| Morphosys, US Inc. | 1 | $25 |
| Merck | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$241
- MOUNJARO$232
- SOTAGLIFLOZIN$200
- XARELTO$100
- JARDIANCE$100
How this compares
$4,086 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 176 | $120,174 |
| FarxigaDapagliflozin Propanediol | 80 | $101,147 |
| XareltoRivaroxaban | 117 | $82,491 |
| TrulicityDulaglutide | 39 | $63,142 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 44 | $53,612 |
| JardianceEmpagliflozin | 35 | $53,127 |
| TradjentaLinagliptin | 32 | $36,306 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $36,036 |
| SynthroidLevothyroxine Sodium | 273 | $34,645 |
| OzempicSemaglutide | 23 | $27,068 |
| Spiriva RespimatTiotropium Bromide | 43 | $22,985 |
| ProliaDenosumab | 12 | $21,682 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $20,118 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $19,196 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 63 | $17,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Jardiance, Tradjenta, Synjardy Xr, Spiriva Respimat | $501 | $202,067174 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $944 | $120,911146 claims |
| PfizerEliquis | $74 | $120,174176 claims |
| Johnson & JohnsonXarelto | $457 | $82,491117 claims |
| Lilly USA, LLCTrulicity | $339 | $63,14239 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $451 | $46,572104 claims |
| AbbVieSynthroid | $70 | $34,645273 claims |
| Novo NordiskOzempic | $150 | $27,06823 claims |
| AmgenProlia | $71 | $21,68212 claims |
| Sanofi-aventis U.S. LLCLantus | $200 | $5,29960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Bayamon
- Sixto MedinaBayamon$15K
- Graciela Latalladi OrtegaBayamon$11K
- Pedro Roman EyxarchBayamon$9K
- Neisa Torres ReyesBayamon$8K
- Luis FortiBayamon$8K
- Carlos AcostaBayamon$7K
- Jose Aviles MunozBayamon$6K
- Steven CruzBayamon$6K
- Lionel Velez MontijoBayamon$6K
- Wanda Beltran VirellaBayamon$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.